PMID-sentid	Pub_year	Sent_text	comp_official_name	comp_offset	protein_name	organism	prot_offset
31041834-4	2019	In this study, aimed at characterizing the mutational status of SMO, BRAF, HRAS, KRAS, NRAS and FGFR2 in CAA, we used RNA sequencing, Sanger sequencing and restriction fragment length polymorphism assays to demonstrate that 94% of CAA (n = 16) harbour a somatic HRAS p.Q61R mutation.	caa	105-108	KRAS proto-oncogene, GTPase	Canis lupus familiaris	81-85
26783265-7	2016	Finally upon the switching on of activated K-Ras expression which induces luminal cell filling, ceramide and LacCer are increased.	Ceramides	96-104	KRAS proto-oncogene, GTPase	Canis lupus familiaris	43-48
26783265-7	2016	Finally upon the switching on of activated K-Ras expression which induces luminal cell filling, ceramide and LacCer are increased.	LacCer	109-115	KRAS proto-oncogene, GTPase	Canis lupus familiaris	43-48
10397446-7	1998	The rate of K-ras mutations in plutonium-induced lung tumors described herein (8%) was greater than previously described in canine plutonium-induced lung tumors (0%), but was less than that which we have described in spontaneous canine lung cancer (16%), less than that reported for human spontaneous non-small cell lung cancer (13-36%) and less than that described in rats with spontaneous lung cancer (40%) or lung tumors following 239Pu inhalation exposure (46%).	Plutonium	31-40	KRAS proto-oncogene, GTPase	Canis lupus familiaris	12-17
10397446-7	1998	The rate of K-ras mutations in plutonium-induced lung tumors described herein (8%) was greater than previously described in canine plutonium-induced lung tumors (0%), but was less than that which we have described in spontaneous canine lung cancer (16%), less than that reported for human spontaneous non-small cell lung cancer (13-36%) and less than that described in rats with spontaneous lung cancer (40%) or lung tumors following 239Pu inhalation exposure (46%).	Plutonium	131-140	KRAS proto-oncogene, GTPase	Canis lupus familiaris	12-17
10397446-7	1998	The rate of K-ras mutations in plutonium-induced lung tumors described herein (8%) was greater than previously described in canine plutonium-induced lung tumors (0%), but was less than that which we have described in spontaneous canine lung cancer (16%), less than that reported for human spontaneous non-small cell lung cancer (13-36%) and less than that described in rats with spontaneous lung cancer (40%) or lung tumors following 239Pu inhalation exposure (46%).	Plutonium-239	434-439	KRAS proto-oncogene, GTPase	Canis lupus familiaris	12-17
8606928-0	1996	p53, erbB-2 and K-ras gene alterations are rare in spontaneous and plutonium-239-induced canine lung neoplasia.	Plutonium-239	67-80	KRAS proto-oncogene, GTPase	Canis lupus familiaris	16-21
35325610-0	2022	Bisphenol A exposure triggers the malignant transformation of prostatic hyperplasia in beagle dogs via cfa-miR-204/KRAS axis.	bis(4-hydroxyphenyl)sulfone	0-9	KRAS proto-oncogene, GTPase	Canis lupus familiaris	115-119
35325610-6	2022	Based on microRNA (miRNA) microarray screening and functional enrichment analysis, BPA might facilitate the progression of prostate tumorigenesis in beagle dogs via cfa-miR-204 and its downstream target KRAS oncogene.	bisphenol A	83-86	KRAS proto-oncogene, GTPase	Canis lupus familiaris	203-207
35325610-8	2022	These findings provide a series of underlying targets for preventing the initiation and metastasis of BPA-induced prostatic hyperplasia and tumorigenesis, while the regulatory relationship headed with KRAS requires further investigation.	bisphenol A	102-105	KRAS proto-oncogene, GTPase	Canis lupus familiaris	201-205
29970615-4	2018	Here we examine the mechanism of action of oxanthroquinone G01 (G01), a recently described inhibitor of KRAS PM localization.	oxanthroquinone g01	43-62	KRAS proto-oncogene, GTPase	Canis lupus familiaris	104-108
29970615-4	2018	Here we examine the mechanism of action of oxanthroquinone G01 (G01), a recently described inhibitor of KRAS PM localization.	2-(N,N-dimethylamino)ethyl-4-ethoxybenzoate	59-62	KRAS proto-oncogene, GTPase	Canis lupus familiaris	104-108
24875924-1	2014	polyketides as modulators of K-Ras localisation.	Polyketides	0-11	KRAS proto-oncogene, GTPase	Canis lupus familiaris	29-34
1324792-2	1992	Canine K-ras was analyzed by direct sequencing of polymerase chain reaction products generated with oligonucleotide primers derived from the human K-ras sequence.	Oligonucleotides	100-115	KRAS proto-oncogene, GTPase	Canis lupus familiaris	7-12